Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Investigator's Choice in Advanced Melanoma
NCT01721746Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2012
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of nivolumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective Response Rate at 38 months and Overall Survival at 96 months. Started Dec 2012; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01721746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721746.